Figure S2


A
Schizonticide (modeled)
Untreated (modeled)
Treated, Schizonticide (- Day 0, modeled)
Untreated (- Day 0, modeled)
Mean of SP field trials
SP trials envelope
Percentage Gametocytemic After Treatment
Days Post Treatment


C
ACT, mild, no late stage effects (modeled)
ACT, mild (modeled)
ACT, moderate (modeled)
ACT, strong (modeled)
Mean of ACT field trials
ACT trials envelope
Percentage Gametocytemic After Treatment
Days Post Treatment


B
CQ, mild (model)
CQ, moderate 1 (modeled)
CQ, moderate 2 (modeled)
CQ, strong (model)
Mean of CQ field trials
CQ trials envelope
Percentage Gametocytemic After Treatment
Days Post Treatment


D
ACT, mild, no late stage effects (modeled)
ACT, mild (modeled)
ACT, moderate (modeled)
ACT, strong (modeled)
Mean of ACT field trials (2 omitted)
ACT trials envelope (2 omitted)
Percentage Gametocytemic After Treatment
Days Post Treatment


E
ACT+PQ, moderate <day 2> (model)
ACT+PQ, moderate <day 0> (model)
ACT+PQ, strong <day 2> (model)
ACT+PQ, strong <day 0> (model)
Mean of ACT+PQ field trials
ACT+PQ trials envelope
Percentage Gametocytemic After Treatment
Days Post Treatment